SCHEMBL25792918

SCHEMBL25792918

O=C(OC1C2CC(C3CCCC32)C1OC(=O)c1cccc2ccccc12)c1cccc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGALS9 O00182 2/20 0.46
LGALS1 P09382 2/20 0.46
LGALS3 P17931 2/20 0.46
LGALS7; LGALS7B P47929 2/20 0.46
LGALS8 O00214 1/20 0.46
GAA P10253 2/20 0.43
POLB P06746 2/20 0.43
KMT2A Q03164 1/20 0.43
NR4A1 P22736 1/20 0.42
NR4A2 P43354 1/20 0.42
NR4A3 Q92570 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
BCHE P06276 1/20 0.41
KDM2B Q8NHM5 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
MMP3 P08254 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
ADRB2 P07550 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24278714 1.00 LGALS9 (0.46) LGALS9LGALS1LGALS3LGALS7; LGALS7BLGALS8
SCHEMBL24278806 0.97 LGALS9 (0.46) LGALS9LGALS1LGALS3LGALS7; LGALS7BLGALS8
SCHEMBL27105760 0.97 LGALS9 (0.46) LGALS9LGALS1LGALS3LGALS7; LGALS7BLGALS8
SCHEMBL24278831 0.84 LGALS9 (0.44) LGALS9LGALS1LGALS3LGALS7; LGALS7BLGALS8
SCHEMBL24278608 0.82 LGALS9 (0.41) LGALS9LGALS1LGALS3LGALS7; LGALS7BLGALS8
SCHEMBL27499333 0.81 KMT2A (0.53) LGALS9LGALS1LGALS3LGALS7; LGALS7BLGALS8
SCHEMBL24278720 0.80 NPC1 (0.42) BCHELMNA
SCHEMBL28015205 0.80 BCHE (0.46) LGALS9LGALS1LGALS3LGALS7; LGALS7BLGALS8
SCHEMBL24278633 0.79 LGALS9 (0.40) LGALS9LGALS1LGALS3LGALS7; LGALS7BLGALS8
SCHEMBL24282342 0.79 LGALS9 (0.40) LGALS9LGALS1LGALS3LGALS7; LGALS7BLGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067763-A1 SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER MITSUI CHEMICALS, INC. (JP) 2024-02-29 US disclosed
US-20240067763-A1 SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER MITSUI CHEMICALS, INC. (JP) 2024-02-29 US disclosed
US-20240025838-A1 ESTER COMPOUND MITSUI CHEMICALS, INC. (JP) 2024-01-25 US disclosed
US-20240025838-A1 ESTER COMPOUND MITSUI CHEMICALS, INC. (JP) 2024-01-25 US disclosed
EP-4206182-A1 ESTER COMPOUND Mitsui Chemicals, Inc. (JP) 2023-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025838-A1 ESTER COMPOUND NR1H3, CYP4A11, H1-4 LGALS9 4368/4885LGALS1 4106/4885LGALS3 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.